Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA256329

Local Sample ID:	Arabic Gum-T05-02-6696
Subject ID:	SU002653
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002665
Treatment Summary:	For intervention group, Arabic gum in the form of powder twice daily was given, at the dose patients are taking usually over the counter (40 grams of GA in the form of instantly soluble granules to be dissolved in a glass of water or juice and drink it daily for the assigned study period. While for the control group, a placebo was given in the same shape and taste and same frequency. Participants in both groups underwent a 24-hour urine collection for creatinine, protein, and volume at baseline and every three months. eGFR was calculated using the CKD-epi equation [add ref], and lab tests, including serum creatinine, electrolytes, uric acid, serum albumin, phosphate, calcium, PTH, Complete Blood Count (CBC), fasting lipid profile, and urinalysis, were performed at baseline and at 3-month intervals for a year. The objectives of the study were to assess the impact of the intervention on various parameters, including a reduction in the eGFR and the rate of the decline, a decrease in proteinuria, changes in uric acid, electrolytes, calcium, phosphate, vitamin D, and PTH levels, effects on edema, body weight, blood pressure, and anemia parameters.

Treatment ID:

TR002665

Treatment Summary:

For intervention group, Arabic gum in the form of powder twice daily was given, at the dose patients are taking usually over the counter (40 grams of GA in the form of instantly soluble granules to be dissolved in a glass of water or juice and drink it daily for the assigned study period. While for the control group, a placebo was given in the same shape and taste and same frequency. Participants in both groups underwent a 24-hour urine collection for creatinine, protein, and volume at baseline and every three months. eGFR was calculated using the CKD-epi equation [add ref], and lab tests, including serum creatinine, electrolytes, uric acid, serum albumin, phosphate, calcium, PTH, Complete Blood Count (CBC), fasting lipid profile, and urinalysis, were performed at baseline and at 3-month intervals for a year. The objectives of the study were to assess the impact of the intervention on various parameters, including a reduction in the eGFR and the rate of the decline, a decrease in proteinuria, changes in uric acid, electrolytes, calcium, phosphate, vitamin D, and PTH levels, effects on edema, body weight, blood pressure, and anemia parameters.